Results 61 to 70 of about 11,211 (144)

Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysisResearch in context

EClinicalMedicine
Summary: Background: Dolutegravir and bictegravir are frequently prescribed second-generation integrase strand transfer inhibitors. Although sex and gender influence drug pharmacokinetics, little is known about the differences in side effects ...
Zhou Fang, Tetiana Povshedna, Rowan Patterson, Erin Ready, Helene C.F. Cote, Melanie C.M. Murray, Elizabeth M. King   +6 more
doaj   +1 more source

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

Drug Design, Development and Therapy, 2015
Christopher E Kandel,1 Sharon L Walmsley1,21Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Division of Infectious Diseases, University Health Network, Toronto, ON, CanadaAbstract: Dolutegravir is the newest integrase strand transfer
Kandel CE, Walmsley SL
doaj  

Perceptions of dolutegravir-based regimen use among people living with HIV in Limpopo province: A qualitative study

Curationis
Background: HIV and AIDS continues to be a critical public health challenge, with sub-Saharan Africa shouldering the heaviest burden. Progress towards disease management has been implemented over the years, and antiretroviral therapy (ART) has been the ...
Zandile R. Sibeko, Boitumelo J. Molato, Salaminah S.P. Moloko-Phiri   +2 more
doaj   +1 more source

Dyslipidemia and Its Associated Factors Among People Living With HIV on Dolutegravir-Based Antiretroviral Therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: A Cross-Sectional Study

AIDS Research and Treatment
Conclusion: The prevalence of dyslipidemia among people living with HIV on a dolutegravir-based ART was high, occurring in nearly three-quarters of the participants.
Mohammed Jemal, Adane Adugna, Mamaru Getinet, Baye Ashenef, Gelagey Baye, Desalegn Abebaw, Zigale Hibstu Teffera, Wastina Bitewlign, Anemut Tilahun, Nuredin Chura Waritu, Tabarak Malik, Enyew Fenta Mengistu   +11 more
doaj   +1 more source

Effectiveness of dolutegravir-based treatment among HIV/AIDS patients in Nkembo Outpatient Treatment Center, Gabon

AIDS Research and Therapy
Background HIV/AIDS therapy continues to make an enormous contribution to improving the well-being of HIV/AIDS patients globally. In Gabon, dolutegravir is administered to HIV/AIDS patients from first-line treatment.
Christian Mangala, Rolf Moukanda-Ifoundou, Denis Maulot-Bangola, Alain Moutsinga, Christian Mombo-Maganga, Serge Christian Okolongo-Mayani, Brice Ongali, Guy Joseph Lemamy, Rachyda Massolou-Outata   +8 more
doaj   +1 more source

Potential benefit of dolutegravir once daily: efficacy and safety

HIV/AIDS: Research and Palliative Care, 2013
Alessandra Fantauzzi,1 Ombretta Turriziani,2 Ivano Mezzaroma11Department of Clinical Medicine, 2Department of Molecular Medicine, Sapienza, University of Rome, Rome, ItalyAbstract: The viral integrase enzyme has recently emerged as a primary alternative ...
Fantauzzi A, Turriziani O, Mezzaroma I
doaj  

Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania

AIDS Research and Therapy
Background The World Health Organization recommends dolutegravir-based antiretroviral therapy (ART) as the preferred first-line regimen for HIV treatment.
Revocatus T. Majula, Clement N. Mweya
doaj   +1 more source

Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women

CPT: Pharmacometrics & Systems Pharmacology
Optimal dosing in pregnant and lactating women requires an understanding of the pharmacokinetics in the mother, fetus, and breastfed infant. Physiologically‐based pharmacokinetic (PBPK) modeling can be used to simulate untested scenarios and hence ...
Jia Ning, Amita Pansari, Karen Rowland Yeo, Aki T. Heikkinen, Catriona Waitt, Lisa M. Almond   +5 more
doaj   +1 more source

Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens. [PDF]

Open Forum Infect Dis
Castagna A, Marcon I, Du F, Li B, Wang M, Clark A, Donovan C, Jones B, Prakash M.   +8 more
europepmc   +1 more source

Pharmaco-economic profile, effectiveness, and safety of a dolutegravir based first line ART regimen among people living with HIV in South Gujarat. [PDF]

Indian J Med Res
Sojitra B, Patel C, Bhatt KN, Pandya S, Shah P, Shah A, Patel J, Adwani C, Panchal V.   +8 more
europepmc   +1 more source